



CORPORATE GOVERNANCE STATEMENT 2024

The following statement relates to Dr. Martens plc (the Company) for the year ended 31 March 2024 (FY24). It provides insight into how we applied the Principles of the UK Corporate Governance Code 2018 (the Code) during FY24, with cross-referencing included where applicable to indicate where further information may be found in our FY24 Annual Report.

We confirm that, throughout FY24, we confirm that the Company applied the Principles and complied with the Provisions of the Code throughout FY24.

A copy of the Code is available from the Financial Reporting Council's website, [here](#).

The FY24 Annual Report can be accessed at drmartensplc.com, [here](#).

Provisions of the Code – areas of further explanation

Code Provision 9 requires that the Chair of a company should be independent on appointment when assessed against the criteria set out in the Code (Provision 10).

The Board confirms that, in accordance with Provision 9, Paul Mason was independent on his appointment to the Board. Paul has held various roles within the Group (including acting as Executive Chairman for a period) and, as a result, the Board does not consider him to meet the specific independence criteria set out in Provision 10. Nevertheless, the Board is confident in Paul's continued chairmanship on the basis that his leadership, extensive knowledge of the Group's business and significant retail and consumer brand experience are in the best interests of the Company and shareholders as a whole.

SECTION 1: BOARD LEADERSHIP AND COMPANY PURPOSE

A

A successful company is led by an effective and entrepreneurial board, whose role is to promote the long- term sustainable success of the company, generating value for shareholders and contributing to wider society.

The Board's primary responsibility is leading the Company to drive sustainable, profitable growth globally and deliver long-term value for all our stakeholders. It sets a clear tone from the top by providing entrepreneurial leadership of the business and promoting custodianship over our brand. The Board holds itself accountable for demonstrating these attributes and expects all our people at Dr. Martens to exhibit a long-term custodian mindset.

Our FY24 Governance report details the structure, processes and controls that enable the Board to lead the Company effectively and promote its long-term success. During the year, the Company (led by the Board) continued to focus on delivering the DOCS strategy. We provided shareholder returns via a share buyback programme and via our progressive dividend policy. We have augmented the Board's effectiveness through the recruitment of an experienced Chief Financial Officer, Giles Wilson. The Board has also been clear on the importance of facing the challenges encountered during the year, for example wholesale demand in the US, by taking steps to elevate the brand in this key market.

June 2024

The ways in which we contribute to wider society are articulated through our long-term commitments under our 'Planet, Product, People' sustainability strategy, which is detailed in depth within our FY24 Sustainability report, which also contains our disclosures relating to TCFD compliance, from page 75.

Location of relevant information in FY24 Annual Report:

FY24 highlights P1

Sustainability report P46

How we create value P16

B

The board should establish the company's purpose, values and strategy, and satisfy itself that these and its culture are aligned. All directors must act with integrity, lead by example and promote the desired culture.

The Board confirms that it has established the Company's purpose, values and strategy, which are set out in the Strategic report (pages 1 - 84), and that these form an intrinsic part of the Dr. Martens culture.

The Board is confident that the Dr. Martens culture is well-established across the global business, that it strongly connects with and is 'lived' by our people and continues to support the ongoing and successful delivery of our strategy. The Board monitors the alignment of our purpose, values and strategy with our culture in a number of ways, including our annual employee Engagement and Inclusion Survey, regular updates at Board meetings from senior leadership on particular focus areas and initiatives and feedback from the Employee Listening Groups facilitated by our Employee Representative Non-Executive Director, Robyn Perriss, held throughout the year.

The Board believes that Board members continue to act with integrity and conduct themselves in a manner that aligns with and promotes our culture. These are non-negotiable attributes for any new Board appointment and were factored into the brief set by the Nomination Committee for the search for a new Chief Financial Officer during FY24.

Location of relevant information in FY24 Annual Report:

Nomination Committee Report P108

Strategic report P1

Stakeholder engagement P18

Our Culture P106

Nomination Committee report P108

C

The board should ensure that the necessary resources are in place for the company to meet its objectives and measure performance against them. The board should also establish a framework of prudent and effective controls, which enable risk to be assessed and managed.

June 2024

We confirm that the necessary resources are in place to ensure that the Company meets its objectives and measures performance against them. Performance is measured with reference to clear financial and non-financial KPIs, which are set out on pages 30 and 31 of our FY24 Annual Report.

Our internal controls framework, which enables the business and Board (through the Audit and Risk Committee) to effectively assess and manage our key risks, is described from page 38 and in the report of the Audit and Risk Committee on page 134 of our FY24 Annual Report. Our risk management processes remain integrated with our overall approach to governance at Dr. Martens, as described throughout this Governance report, with oversight delegated by the Board to the Audit and Risk Committee. More information about our principal risks and how they are managed can be found in the Effective risk management section of our FY24 Annual Report.

Location of relevant information in FY24 Annual Report:

Effective risk management P38 - 43

Measuring performance P30 - 31

Audit and Risk Committee report P134

D

In order for the company to meet its responsibilities to shareholders and stakeholders, the board should ensure effective engagement with, and encourage participation from, these parties.

In addition to its accountability to shareholders, a core responsibility of the Board is to represent the interests of the Group's stakeholders and to consider and, where appropriate, factor their needs into its discussions and decision-making. The 'Stakeholder engagement' section of the FY24 Strategic report (pages 18 -21) and pages 101 – 104 of the Governance Report clearly identify our key stakeholder groups, describes their interests and outlines some of the ways in which the Board has sought, and continues to seek, to account for its relationships with each of them, as well as how this helps inform its decision-making processes.

Location of relevant information in FY24 Annual Report:

Stakeholder engagement P18 - 21 and 101 – 104.

E

The board should ensure that workforce policies and practices are consistent with the company's values and support its long-term sustainable success. The workforce should be able to raise any matters of concern.

The Company's 'Speak Up' Policy governs how our people can safely raise any matters of concern, such as suspected illegal or unethical business practices impacting the business. A confidential incident reporting facility is available for circumstances where an individual wishes to report an issue anonymously, which is provided by an independent specialist firm. Oversight of this process is delegated to the Audit and Risk Committee, which receives updates on specific issues raised and the Company's response to them. This Policy was reviewed in FY24.

On joining the business, all employees are issued with a copy of the DOctrine, our global code of conduct, which is rooted in our ethos of doing the right thing and acting with integrity. The DOctrine defines how we do business at Dr. Martens and sets out the behaviours and standards expected of all employees as custodians of the Dr. Martens brand. This covers areas such as human rights and ethical trade, health and safety, anti-bribery, malpractice and harassment.

Employees are also able to discuss any issues or challenges they encounter with the Employee Representative Non- Executive Director during their regular listening sessions. These are confidential 'safe spaces' where employees speak their minds openly and honestly. An anonymised, high-level summary of the themes of these discussions is reported back to the Board, with follow up actions agreed as needed.

Location of relevant information in FY24 Annual Report:

Stakeholder engagement P18 - 21 and 101 – 104.

Audit and Risk Committee report P134

SECTION 2: DIVISION OF RESPONSIBILITIES

F

The chair leads the board and is responsible for its overall effectiveness in directing the company. They should demonstrate objective judgement throughout their tenure and promote a culture of openness and debate. In addition, the chair facilitates constructive board relations and the effective contribution of all non- executive directors, and ensures that directors receive accurate, timely and clear information.

The Board notes that, when assessed against the independence criteria set out in Provision 10 of the Code, Paul Mason was independent on his appointment to the Board in 2015 but was not considered independent on the Company's admission to listing in 2021. Page 110 of our FY24 Annual Report sets out the reasons why the Board remains confident that Paul's continued chairmanship is in the best interests of the Company and its stakeholders.

The Chairman is mindful of his role in leading the Board, which includes ensuring that it discharges its responsibilities to the Company and other stakeholders effectively, fostering constructive relationships between, and facilitating effective contributions from, all Board members. The Board has agreed that Paul Mason continues to be effective in this role, demonstrates objective judgement and promotes a culture of open, honest debate in the boardroom.

The effectiveness of the Board in directing the Company is assessed annually as part of the Board Evaluation process, which in line with the requirements of the Code is externally facilitated at least every three years.

The internal Board Evaluation led by the Chairman, Company Secretary and Senior Independent Director in FY24 found that the Board was focused on the right priorities, led by a trusted Chair and that it continued to operate effectively overall. Full details of the FY24 Board Evaluation can be found on pages 114 and 115.

The Chairman is supported in supplying the Board with accurate, timely and clear information by the Company Secretary, who ensures that such information is available and that it flows from the business to the Board and its Committees to facilitate high-quality discussion and debate.

Location of relevant information in FY24 Annual Report:

Delegation of responsibilities P98

Effectiveness and independence of the Chair of the Board P110

Board Evaluation P114 – 115

G

The board should include an appropriate combination of executive and non- executive (and, in particular, independent non-executive) directors, such that no one individual or small group of individuals dominates the board’s decision-making. There should be a clear division of responsibilities between the leadership of the board and the executive leadership of the company’s business.

Code Provision 11 stipulates that at least half the Board (excluding the Chair) should be Non-Executive Directors whom the Board considers to be independent, while Provision 10 requires that those considered to be independent are identified as such in the Annual Report. Over half of our Board (excluding the Chairman) comprised Independent Non-Executive Directors during FY24. The memberships of both the Remuneration and Audit and Risk Committees comprise Independent Non-Executive Directors only, while the Nomination Committee comprises all of the Independent Non-Executive Directors, the Non-Independent Non-Executive Director and the Chairman.

The Board confirms that it assessed the independence of the Non-Executive Directors as part of the FY24 Board Evaluation process. It has determined that all of the Non-Executive Directors continued to demonstrate independence in both character and judgement during FY24. Each of the Non-Executive Directors that were considered by the Board to be independent during FY24 are identified in our FY24 Annual Report on page 88 and in their biographies on pages 92 to 94 and available at www.drmartensplc.com.

The Board has also determined that, with the exception of Tara Alhadeff, the Non-Executive Directors remain free from relationships or circumstances which may (or could appear to) affect their judgement. More information about Tara’s length of service and relationship with the Company’s largest shareholder, IngreLux S.à.r.l (which is wholly owned by funds advised by Permira Advisers LLP), is provided on page 98 of the FY24 Annual Report.

Tara was appointed to the Board by IngreLux S.à.r.l pursuant to its relationship agreement with the Company. This agreement permits IngreLux S.à.r.l to appoint one Non-Executive Director to the Board for so long as it retains control of 10% or more of the votes able to be cast on all (or substantially all) matters at any general meeting held by the Company. As such, the Board does not consider Tara to meet the specific independence criteria set out in Provision 10 of the Code.

The roles of Chair and Chief Executive are separately held, with distinct responsibilities that are defined in writing and reviewed by the Board at least annually. These, together with a description of the roles and responsibilities of the Senior Independent Director, are available to view at www.drmartensplc.com.

To maximise its effectiveness and ensure sufficient time and attention can be devoted to its key priorities, the Board has delegated authority in certain areas to the Audit and Risk, Remuneration and Nomination Committees. Clear terms of reference are in place for each of these Committees, which are reviewed by the Board at least annually. More information on how the Board delegates authority to Committees and the wider business can be found on page 98.

Location of relevant information in FY24 Annual Report:

June 2024

Board biographies P92 -94

Delegation of responsibilities P98

Agreements with controlling shareholder P147

H

Non-executive directors should have sufficient time to meet their board responsibilities. They should provide constructive challenge, strategic guidance, offer specialist advice and hold management to account.

Details of Board meetings held in FY24, including attendance at each meeting, can be found on page 95 of the FY24 Annual Report. The equivalent information in relation to the Audit and Risk, Remuneration and Nomination Committees is also summarised on page 95, while more detail can be found in the respective reports of each Committee from pages 134, 116 and 108 respectively.

Each of the Non-Executive Directors has confirmed that they continue to be able to meet the Company's expectations of them and to allocate sufficient time to discharge their duties as Directors effectively and the Board is satisfied that this continues to be the case. Directors' external commitments are monitored by the Board on an ongoing basis, with the assistance of the Company Secretariat function, to ensure that they remain able to allocate sufficient time to their duties to the Company.

Non-Executive Directors are expected to avoid holding an excessive number of external appointments; however, the Board recognises that these roles can vary significantly in terms of their complexity and required time commitment, so has agreed to assess them on a case-by-case basis. When doing so, the Board considers the number of board positions that the Director in question holds at other public companies alongside the likely 'size' of their new role. It also takes into account externally published guidance and proxy voting guidelines to ensure the principles of major investors in respect of 'overboarding' are considered.

The Board is satisfied that the quantity of external interests held by each of the Non-Executive Directors remains at an appropriate level and that they do not give rise to any conflicts of interest.

Location of relevant information in FY24 Annual Report:

Governance Report P95 and 98

Audit and Risk Committee report P134

Nomination Committee report P108

Remuneration Committee report P116

I

The Board, supported by the company secretary, should ensure that it has the policies, processes, information, time and resources it needs in order to function effectively and efficiently.

The Company Secretary provides support to the Chairman and the Board on all matters relating to corporate governance at Dr. Martens and all Board members have access to her advice as and when it is required.

The Company Secretary's duties also include ensuring that Board procedures, Group governance policies and all applicable rules and regulations are in place and complied with.

All Group policies are required to adhere to the policy governance process, which provides the end-to-end framework for the authoring, approval, communication, training and roll-out of policies and stipulates the different stages at which they should be reviewed from the point at which the need for a policy is identified through to its final approval. The Board has delegated oversight of this process to the Audit and Risk Committee, which considers the framework within its annual update from the Compliance function. The Audit and Risk Committee retains a standing item on its agenda to consider any new or renewed policies as and when required.

The matters over which the Board retains sole authority are clearly set out in its Schedule of Matters Reserved for the Board, which can be found at www.drmartensplc.com.

Location of relevant information in FY24 Annual Report:

Audit and Risk Committee report P134

Delegation of responsibilities P98

SECTION 3: COMPOSITION, SUCCESSION AND EVALUATION

The Nomination Committee comprises all of the Company's Non-Executive Directors (the majority of whom are independent) and the Chair of the Board. Andrew Harrison joined the Committee on his appointment to the Board in May 2023, while Ije Nwokorie stepped down on commencing his new role as Chief Brand Officer in February 2024.

The members of the Committee and their attendance at meetings during the year are disclosed on page 108 of the Annual Report. The Committee's Terms of Reference are available at www.drmartensplc.com.

The Committee's key responsibilities include:

- Recommending potential Board and senior management appointments and reappointments to the Board.
- Overseeing the inductions of new Board members and the ongoing training, as appropriate, for the Board.
- Reviewing and making recommendations to the Board in relation to Board and senior management succession planning, including ensuring plans are in place for an orderly succession.
- Overseeing the development of a diverse succession pipeline and the Company's policy on Board, senior management and workforce diversity and inclusion.
- Reviewing and monitoring the effectiveness of the Company's policies, objectives and strategies relating to diversity and inclusion.

J

Appointments to the board should be subject to a formal, rigorous and transparent procedure, and an effective succession plan should be maintained for board and senior management.

Both appointments and succession plans should be based on merit and objective criteria and, within this context, should promote diversity of gender, social and ethnic backgrounds, cognitive and personal strengths.

The report of the Nomination Committee in the FY24 Annual Report (from page 108) sets out the Board's processes and procedures in relation to new appointments, with specific reference to the process undertaken to identify and appoint Giles Wilson, Andrew Harrison's induction

process and the CEO succession process, as well as its approach to Board and senior management diversity. The Board, through the Nomination Committee, is satisfied that Giles Wilson's appointment process and the process which led to the identification of Ije Nwokorie and Kenny Wilson's successor as CEO were exhaustive and resulted in the right appointments for the Board and business.

The Nomination Committee keeps the Board's skills matrix, the tenure of each Board member and the succession plans relating to the Board and GLT (which comprises the first layer of management below Board level) under review. Looking ahead to FY24, senior succession will be a key area of focus for the Nomination Committee as detailed on pages 109 and 110 of the FY24 Annual Report.

Location of relevant information in FY24 Annual Report:

Nomination Committee report P109 and 110

K

The board and its committees should have a combination of skills, experience and knowledge. Consideration should be given to the length of service of the board as a whole and membership regularly refreshed.

Details of the tenure, diversity, range of skills, experience and backgrounds of our Board members are available in their individual biographies on www.drmartensplc.com and on 92-94 of the FY24 Annual Report. A Board skills matrix is kept under review by the Nomination Committee and used to guide and inform its succession plans and the criteria for any prospective future appointments.

With the exception of Andrew Harrison, who joined the Board on 1 May 2023, all of our Independent Non-Executive Directors are now in the fourth year of the recommended maximum nine-year term of service set out in the Code. Our longest-serving Director is Tara Alhadeff, appointed in May 2015, who has served nine years on the Board.

Location of relevant information in FY24 Annual Report:

Board at a glance P90 - 91

Board biographies P92 - 94

L

Annual evaluation of the board should consider its composition, diversity and how effectively members work together to achieve objectives.

Individual evaluation should demonstrate whether each director continues to contribute effectively.

An overview of the FY24 internal Board Evaluation process, including insights and outcomes, can be found within the report of the Nomination Committee from page 108 of the FY24 Annual Report. Details of the contributions of each individual Board member in supporting the Company's strategy and long-term, sustainable success are set out on pages 92-94.

June 2024

Externally facilitated Board reviews are held at least every three years. The Company's last externally facilitated Board Review took place in 2022 and therefore the next externally facilitated Board review will be in FY25. Details of this will be disclosed in our FY25 Annual Report.

Location of relevant information in FY24 Annual Report:

Board Evaluation P114 - 115

Board biographies P92 - 94

SECTION 4: AUDIT, RISK AND INTERNAL CONTROL

During FY24, the Company's Audit and Risk Committee comprised four Independent Non-Executive Directors: Lynne Weedall, Ije Nwokorie, Andrew Harrison and Robyn Perriss as Committee Chair. Andrew formally joined the Committee on 1 May 2023 and was present along with every other Committee member at all of its meetings during the year. Ije stepped down from the Committee on his appointment as Chief Brand Officer in February 2024.

The full terms of reference of the Committee are available at www.drmartensplc.com. The attendance of Committee members at meetings during the year is disclosed on page 134 of the Annual Report.

The key responsibilities of the Committee include:

- Monitoring the integrity of the Group's Annual Reports and financial statements and any other formal announcements relating to the Group's financial performance, and reviewing the significant financial reporting judgements made in connection with their preparation.
- Monitoring and reviewing the adequacy and effectiveness of the Company's internal financial controls and internal control and risk management systems.
- Overseeing and maintaining an appropriate relationship with the Company's external auditor and reviewing the independence, objectivity and effectiveness of the audit process.
- Ensuring that Internal Audit arrangements are appropriate and effective.
- Ensuring that fraud prevention and whistleblowing arrangements are embedded to minimise the potential for fraud and financial impropriety.

M

The board should establish formal and transparent policies and procedures to ensure the independence and effectiveness of internal and external audit functions and satisfy itself on the integrity of financial and narrative statements.

We confirm that the integrity of the financial and narrative statements within the Company's annual and interim accounts was monitored during the year through the Audit and Risk Committee and that, on the recommendation of that Committee, the Board is satisfied that these are at the required level. We have also established formal and transparent policies and procedures to ensure the Internal Audit function and the external auditor are able to operate independently and effectively.

Location of relevant information in FY24 Annual Report:

N

The board should present a fair, balanced and understandable assessment of the company's position and prospects.

The Board's statement regarding the responsibility of the Directors for preparing the Annual Report and Accounts and the Directors' assessment of the Annual Report and Accounts, taken as a whole, as being fair, balanced and understandable and providing the necessary information for shareholders to assess the Company's position, performance, business model and strategy, is located in the Directors' report section of the FY24 Annual Report.

Location of relevant information in FY24 Annual Report:

Directors' report P144

O

The board should establish procedures to manage risk, oversee the internal control framework, and determine the nature and extent of the principal risks the company is willing to take in order to achieve its long-term strategic objectives.

The Board has overarching responsibility for ensuring that the Group's systems of internal control and risk management are established and effective. It discharges this responsibility through the Audit and Risk Committee, which receives close support from the Internal Audit function through its regular reports and updates on internal control matters and the Group's principal risks. This process assists the Board, through the Audit and Risk Committee, in overseeing the Group's risk management processes, including the nature and placement of risks within the Group Risk Register and monitoring emerging risks, which inform its approach to risk appetite.

We confirm that this process was in place throughout the year under review and up until the date of publication of this Annual Report and has enabled it to carry out a robust assessment of the Group's emerging and principal risks. The assessment of our principal and emerging risks, risk appetite and the Group's processes and procedures to identify and manage risk can be found in the 'Effective risk management' section of the Strategic report.

Location of relevant information in FY24 Annual Report:

Audit and Risk Committee report P134

Effective risk management P38 - 43

SECTION 5: REMUNERATION

The Remuneration Committee currently comprises Lynne Weedall (Chair), Robyn Perriss and Andrew Harrison, all of whom are Independent Non-Executive Directors and provide a balance of skills and experience. Andrew Harrison joined the Committee on 1 May 2023, while Ian Rogers stepped down from the Committee on 1 May 2023.

The full terms of reference of the Committee are available at www.drmartensplc.com. The attendance of Committee members at meetings during the year is disclosed on page 116 of the Annual Report.

The Committee's key responsibilities are to:

- Establish and agree with the Board the Remuneration Policy for the Executive Directors, the Company Secretary, the Global Leadership Team (GLT) (together, the 'Executive Group'), the Chair of the Board and any other senior employees as the Board may determine.
- Determine the individual remuneration packages of the Executive Group, the Chair of the Board and relevant senior employees within the terms of the agreed Remuneration Policy.
- Monitor the remuneration structures and overall levels of remuneration of the Executive Group and relevant senior management and make recommendations to the Board where appropriate.
- Oversee the remuneration of the wider Dr. Martens workforce and ensure that our policy for the senior team is consistently structured and also ensures alignment between incentives and Company culture and values.
- Oversee the operation of the Group's share plans.

P

Remuneration policies and practices should be designed to support strategy and promote long-term sustainable success. Executive remuneration should be aligned to company purpose and values, and be clearly linked to the successful delivery of the company's long-term strategy.

The report of the Remuneration Committee, available from page 116 of the FY24 Annual Report, describes how it has sought to ensure that the Company's remuneration policies and practices support our strategy, promote the long-term, sustainable success of the business and align with our culture.

Location of relevant information in FY24 Annual Report:

Remuneration Committee report P116

Q

A formal and transparent procedure for developing policy on executive remuneration and determining director and senior management remuneration should be established. No director should be involved in deciding their own remuneration outcome.

The Board had delegated responsibility for developing the Company's policy on executive remuneration to the Remuneration Committee and for setting the remuneration of the Executive Directors in line with that policy. The Remuneration Policy was approved by shareholders at the AGM in 2021 and, in accordance with s439A of the Companies Act 2006, will next be tabled for shareholder approval at the AGM in 2024.

The Remuneration Committee is also responsible for agreeing the fees for the Chair of the Board and Non-Executive Directors, and the salaries of the GLT and Company Secretary. We confirm that under no circumstances is any Director involved in deciding their own remuneration outcome.

Location of relevant information in FY24 Annual Report:

Remuneration Committee report P116

Remuneration Policy P120-123